jimmy Turano

BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI

MIKE HAVRILLA-Let me be the first to wish you a Happy Thanksgiving & Merry Christmas. Enjoyed your articles all year.
If I may put in the stocking as a request for the Holidays, when you have the time, can you please give your honest straight forward
opinion, at this current time, your realistic opinion on one stock?
MDRNA INC (MRNA)-IT WOULD BE GREATLY APPRECIATED.

Three Recent Biotech Activist Wins by Carl Icahn

Good Article! I am not surprised at all that 'MRNA' didn't make the list. In fact in 2 years I have never seen any coverage on 'MRNA'
on seeking alpha at all. Why? Especially puzzling, is in two years and up to 4 weeks ago, analysts still have high targeted stock prices.
Last target price was $4.00?. Again why? Investors some times are swayed by these analysts but must clearly understand that they follow the stock, therefore they seem to always show a bright side of great potential appreciation. If you check back since early 2007, they all have been wrong while the stock price has decreased in value. I bring this up, because shareholders are still being mislead today in the market. And if you reacted to the last target price of $4.00, just 4 weeks ago, you have seen once again the stock price go down. Nobody ever investigates these analysts.
They get paid and release new target prices that are not warranted.
Since it goes under the radar, I have brought it to light on seeking alpha for three straight years. Someone must have a voice or the continuing misinformation is fed to shareholders or potential shareholders who think they can get rich overnight.
I wish to thank SEEKINGALPHA for affording me the opportunity
to be heard on their site. September 1, 2009, 'MRNA' is on a weak downtrend and unless they announce a major partnership in the coming days, or a Reverse split, I only see a decreasing stock price regardless what analysts state in their news releases.
This is my opinion.

Alkermes, Lilly, Mannkind: Inhaled Insulin Just Got Interesting

Mr.Shulman, your article regarding inhaled Insulin
was quite interesting. I didn't know that there are two programs left to consider. Now that NVO is out and broke their agreement with 'NSTK' on Jan.16th
according to yesterdays press release, do you think
in your opinion that 'nstk' doesn't have any chances left in the inhaled insulin programs?
Even though the stock price is down almost 80% in the past 12 months, you must admit the company has been around for 24 years already and management still keeps filing for shelf registrations and somebody keeps buying it.